array(40) {
  [0]=>
  string(4) "9059"
  ["article_id"]=>
  string(4) "9059"
  [1]=>
  string(130) "Vertex Announces US FDA Approval of Casgevy (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia"
  ["article_title"]=>
  string(130) "Vertex Announces US FDA Approval of Casgevy (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia"
  [2]=>
  string(150) "BOSTON--(BUSINESS WIRE)--Jan. 16, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration"
  ["short_description"]=>
  string(150) "BOSTON--(BUSINESS WIRE)--Jan. 16, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration"
  [3]=>
  string(251) "BOSTON--(BUSINESS WIRE)--Jan. 16, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved Casgevy™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited..."
  ["description"]=>
  string(251) "BOSTON--(BUSINESS WIRE)--Jan. 16, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved Casgevy™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(133) "https://www.drugs.com/newdrugs/vertex-announces-us-fda-approval-casgevy-exagamglogene-autotemcel-transfusion-dependent-beta-6182.html"
  ["blog_url"]=>
  string(133) "https://www.drugs.com/newdrugs/vertex-announces-us-fda-approval-casgevy-exagamglogene-autotemcel-transfusion-dependent-beta-6182.html"
  [15]=>
  string(19) "2024-01-17 06:01:03"
  ["add_date"]=>
  string(19) "2024-01-17 06:01:03"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9124"
  ["article_id"]=>
  string(4) "9124"
  [1]=>
  string(79) "Legislation to Streamline Drug Patent Litigation Introduced in House and Senate"
  ["article_title"]=>
  string(79) "Legislation to Streamline Drug Patent Litigation Introduced in House and Senate"
  [2]=>
  string(153) "&#nl        Recently introduced bicameral, bipartisan legislation could make it easier for competitors to enter the generic and biosimilar market by putt"
  ["short_description"]=>
  string(153) "&#nl        Recently introduced bicameral, bipartisan legislation could make it easier for competitors to enter the generic and biosimilar market by putt"
  [3]=>
  string(231) "&#nl        Recently introduced bicameral, bipartisan legislation could make it easier for competitors to enter the generic and biosimilar market by putting controls on patent thickets created by pharmaceutical companies.&#nl      "
  ["description"]=>
  string(231) "&#nl        Recently introduced bicameral, bipartisan legislation could make it easier for competitors to enter the generic and biosimilar market by putting controls on patent thickets created by pharmaceutical companies.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(119) "https://www.fdanews.com/articles/213122-legislation-to-streamline-drug-patent-litigation-introduced-in-house-and-senate"
  ["blog_url"]=>
  string(119) "https://www.fdanews.com/articles/213122-legislation-to-streamline-drug-patent-litigation-introduced-in-house-and-senate"
  [15]=>
  string(19) "2024-01-17 04:50:49"
  ["add_date"]=>
  string(19) "2024-01-17 04:50:49"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:51"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9125"
  ["article_id"]=>
  string(4) "9125"
  [1]=>
  string(75) "JAMA Study Analyzes History — And Risks — of AI in Healthcare"
  ["article_title"]=>
  string(75) "JAMA Study Analyzes History — And Risks — of AI in Healthcare"
  [2]=>
  string(153) "&#nl        Delving into the development of AI in healthcare, Google researchers have penned an analysis of how AI has grown from a mere concept in the 1"
  ["short_description"]=>
  string(153) "&#nl        Delving into the development of AI in healthcare, Google researchers have penned an analysis of how AI has grown from a mere concept in the 1"
  [3]=>
  string(286) "&#nl        Delving into the development of AI in healthcare, Google researchers have penned an analysis of how AI has grown from a mere concept in the 1950s to be a dominant force in healthcare today, with leaders facing questions about its risks, problems and possibilities.&#nl      "
  ["description"]=>
  string(286) "&#nl        Delving into the development of AI in healthcare, Google researchers have penned an analysis of how AI has grown from a mere concept in the 1950s to be a dominant force in healthcare today, with leaders facing questions about its risks, problems and possibilities.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(97) "https://www.fdanews.com/articles/213121-jama-study-analyzes-history-and-risks-of-ai-in-healthcare"
  ["blog_url"]=>
  string(97) "https://www.fdanews.com/articles/213121-jama-study-analyzes-history-and-risks-of-ai-in-healthcare"
  [15]=>
  string(19) "2024-01-17 04:45:49"
  ["add_date"]=>
  string(19) "2024-01-17 04:45:49"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:51"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9229"
  ["article_id"]=>
  string(4) "9229"
  [1]=>
  string(67) "Banner Health reduces generalized anxiety with digital therapeutics"
  ["article_title"]=>
  string(67) "Banner Health reduces generalized anxiety with digital therapeutics"
  [2]=>
  string(154) "The health system's behavioral health team is measuring a 40% order-to-enrollment rate, with many patients using the digital tools for more than two h"
  ["short_description"]=>
  string(154) "The health system's behavioral health team is measuring a 40% order-to-enrollment rate, with many patients using the digital tools for more than two h"
  [3]=>
  string(163) "The health system's behavioral health team is measuring a 40% order-to-enrollment rate, with many patients using the digital tools for more than two hours.&#nl"
  ["description"]=>
  string(163) "The health system's behavioral health team is measuring a 40% order-to-enrollment rate, with many patients using the digital tools for more than two hours.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(100) "https://www.healthcareitnews.com/news/banner-health-reduces-generalized-anxiety-digital-therapeutics"
  ["blog_url"]=>
  string(100) "https://www.healthcareitnews.com/news/banner-health-reduces-generalized-anxiety-digital-therapeutics"
  [15]=>
  string(19) "2024-01-17 00:56:22"
  ["add_date"]=>
  string(19) "2024-01-17 00:56:22"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9230"
  ["article_id"]=>
  string(4) "9230"
  [1]=>
  string(51) "HHS Secretary names first Chief Competition Officer"
  ["article_title"]=>
  string(51) "HHS Secretary names first Chief Competition Officer"
  [2]=>
  string(150) "Stacy Sanders will be tasked with supporting competition that can help lower healthcare and prescription drug costs and will coordinate with the FTC a"
  ["short_description"]=>
  string(150) "Stacy Sanders will be tasked with supporting competition that can help lower healthcare and prescription drug costs and will coordinate with the FTC a"
  [3]=>
  string(225) "Stacy Sanders will be tasked with supporting competition that can help lower healthcare and prescription drug costs and will coordinate with the FTC and DOJ to address anticompetitive healthcare technology data practices.&#nl"
  ["description"]=>
  string(225) "Stacy Sanders will be tasked with supporting competition that can help lower healthcare and prescription drug costs and will coordinate with the FTC and DOJ to address anticompetitive healthcare technology data practices.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(89) "https://www.healthcareitnews.com/news/hhs-secretary-names-first-chief-competition-officer"
  ["blog_url"]=>
  string(89) "https://www.healthcareitnews.com/news/hhs-secretary-names-first-chief-competition-officer"
  [15]=>
  string(19) "2024-01-16 23:53:54"
  ["add_date"]=>
  string(19) "2024-01-16 23:53:54"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9306"
  ["article_id"]=>
  string(4) "9306"
  [1]=>
  string(81) "Integration of Abbott and Tandem devices provide new option for diabetic patients"
  ["article_title"]=>
  string(81) "Integration of Abbott and Tandem devices provide new option for diabetic patients"
  [2]=>
  string(152) "Abbott and Tandem Diabetes Care recently announced the wireless integration of Abbottâs FreeStyle Libre 2 Plus continuous glucose monitor with the Ta"
  ["short_description"]=>
  string(152) "Abbott and Tandem Diabetes Care recently announced the wireless integration of Abbottâs FreeStyle Libre 2 Plus continuous glucose monitor with the Ta"
  [3]=>
  string(190) "Abbott and Tandem Diabetes Care recently announced the wireless integration of Abbottâs FreeStyle Libre 2 Plus continuous glucose monitor with the Tandem t:slim X2 insulin pump in the US."
  ["description"]=>
  string(190) "Abbott and Tandem Diabetes Care recently announced the wireless integration of Abbottâs FreeStyle Libre 2 Plus continuous glucose monitor with the Tandem t:slim X2 insulin pump in the US."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(187) "https://www.biopharma-reporter.com/Article/2024/01/16/Integration-of-Abbott-and-Tandem-devices-provide-new-option-for-diabetic-patients?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(187) "https://www.biopharma-reporter.com/Article/2024/01/16/Integration-of-Abbott-and-Tandem-devices-provide-new-option-for-diabetic-patients?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-16 23:27:00"
  ["add_date"]=>
  string(19) "2024-01-16 23:27:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:36"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9207"
  ["article_id"]=>
  string(4) "9207"
  [1]=>
  string(82) "Drug delivery technology provider DelSiTech  receives €10 million investment"
  ["article_title"]=>
  string(82) "Drug delivery technology provider DelSiTech  receives €10 million investment"
  [2]=>
  string(150) "Clinical-stage drug delivery and development company DelSiTech has made the biggest single financing round in its history with the successful completi"
  ["short_description"]=>
  string(150) "Clinical-stage drug delivery and development company DelSiTech has made the biggest single financing round in its history with the successful completi"
  [3]=>
  string(178) "Clinical-stage drug delivery and development company DelSiTech has made the biggest single financing round in its history with the successful completion of a â10 million deal."
  ["description"]=>
  string(178) "Clinical-stage drug delivery and development company DelSiTech has made the biggest single financing round in its history with the successful completion of a â10 million deal."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(166) "https://www.outsourcing-pharma.com/Article/2024/01/16/investment-of-10-million-for-drug-delivery-company-delsitech?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(166) "https://www.outsourcing-pharma.com/Article/2024/01/16/investment-of-10-million-for-drug-delivery-company-delsitech?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-16 22:49:00"
  ["add_date"]=>
  string(19) "2024-01-16 22:49:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:49"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9208"
  ["article_id"]=>
  string(4) "9208"
  [1]=>
  string(102) "GSK to pump £200 million into UK to boost medicine production and buys Aiolos Bio for $1.1 billion "
  ["article_title"]=>
  string(102) "GSK to pump £200 million into UK to boost medicine production and buys Aiolos Bio for $1.1 billion "
  [2]=>
  string(156) "Pharma giant, GSK, plans to invest Â200 million ($253 million) into the UK over the next two years and has acquired Aiolos Bio for $1.1 billion (Â87"
  ["short_description"]=>
  string(156) "Pharma giant, GSK, plans to invest Â200 million ($253 million) into the UK over the next two years and has acquired Aiolos Bio for $1.1 billion (Â87"
  [3]=>
  string(167) "Pharma giant, GSK, plans to invest Â200 million ($253 million) into the UK over the next two years and has acquired Aiolos Bio for $1.1 billion (Â870 million)."
  ["description"]=>
  string(167) "Pharma giant, GSK, plans to invest Â200 million ($253 million) into the UK over the next two years and has acquired Aiolos Bio for $1.1 billion (Â870 million)."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(172) "https://www.outsourcing-pharma.com/Article/2024/01/16/gsk-s-200-million-investment-in-the-uk-and-1.1-billion-acquisition?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(172) "https://www.outsourcing-pharma.com/Article/2024/01/16/gsk-s-200-million-investment-in-the-uk-and-1.1-billion-acquisition?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-16 19:58:00"
  ["add_date"]=>
  string(19) "2024-01-16 19:58:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:49"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9189"
  ["article_id"]=>
  string(4) "9189"
  [1]=>
  string(50) "Summit Medical announces MDR certification success"
  ["article_title"]=>
  string(50) "Summit Medical announces MDR certification success"
  [2]=>
  string(150) "Summit Medical, a specialist in the provision of quality medical products manufactured in the UK, has announced the successful attainment of the Europ"
  ["short_description"]=>
  string(150) "Summit Medical, a specialist in the provision of quality medical products manufactured in the UK, has announced the successful attainment of the Europ"
  [3]=>
  string(200) "Summit Medical, a specialist in the provision of quality medical products manufactured in the UK, has announced the successful attainment of the European Medical Device Regulation (MDR) certification."
  ["description"]=>
  string(200) "Summit Medical, a specialist in the provision of quality medical products manufactured in the UK, has announced the successful attainment of the European Medical Device Regulation (MDR) certification."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(132) "https://www.medicalplasticsnews.com/news/medical-plastics-regulatory-policy-news/summit-medical-announces-mdr-certification-success/"
  ["blog_url"]=>
  string(132) "https://www.medicalplasticsnews.com/news/medical-plastics-regulatory-policy-news/summit-medical-announces-mdr-certification-success/"
  [15]=>
  string(19) "2024-01-16 18:46:37"
  ["add_date"]=>
  string(19) "2024-01-16 18:46:37"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:42"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:42"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9060"
  ["article_id"]=>
  string(4) "9060"
  [1]=>
  string(143) "Dupixent (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement"
  ["article_title"]=>
  string(143) "Dupixent (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement"
  [2]=>
  string(150) "TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. F"
  ["short_description"]=>
  string(150) "TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. F"
  [3]=>
  string(248) "TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent® (dupilumab) in atopic..."
  ["description"]=>
  string(248) "TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent® (dupilumab) in atopic..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(140) "https://www.drugs.com/newdrugs/dupixent-dupilumab-u-s-label-updated-data-further-supporting-atopic-dermatitis-moderate-severe-hand-6184.html"
  ["blog_url"]=>
  string(140) "https://www.drugs.com/newdrugs/dupixent-dupilumab-u-s-label-updated-data-further-supporting-atopic-dermatitis-moderate-severe-hand-6184.html"
  [15]=>
  string(19) "2024-01-16 13:01:34"
  ["add_date"]=>
  string(19) "2024-01-16 13:01:34"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9061"
  ["article_id"]=>
  string(4) "9061"
  [1]=>
  string(135) "U.S. FDA Approves Takeda’s Hyqvia as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"
  ["article_title"]=>
  string(135) "U.S. FDA Approves Takeda’s Hyqvia as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"
  [2]=>
  string(153) "&#nlHyqvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the Only up to Once Monthly (every 2, 3 or 4 weeks) Subcutaneous "
  ["short_description"]=>
  string(153) "&#nlHyqvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the Only up to Once Monthly (every 2, 3 or 4 weeks) Subcutaneous "
  [3]=>
  string(253) "&#nlHyqvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the Only up to Once Monthly (every 2, 3 or 4 weeks) Subcutaneous Immunoglobulin (SCIG) Infusion to Treat CIDP, Can Be Administered by a Healthcare Professional or..."
  ["description"]=>
  string(253) "&#nlHyqvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the Only up to Once Monthly (every 2, 3 or 4 weeks) Subcutaneous Immunoglobulin (SCIG) Infusion to Treat CIDP, Can Be Administered by a Healthcare Professional or..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(135) "https://www.drugs.com/newdrugs/u-s-fda-approves-takeda-s-hyqvia-maintenance-therapy-adults-chronic-inflammatory-demyelinating-6183.html"
  ["blog_url"]=>
  string(135) "https://www.drugs.com/newdrugs/u-s-fda-approves-takeda-s-hyqvia-maintenance-therapy-adults-chronic-inflammatory-demyelinating-6183.html"
  [15]=>
  string(19) "2024-01-16 13:01:24"
  ["add_date"]=>
  string(19) "2024-01-16 13:01:24"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9088"
  ["article_id"]=>
  string(4) "9088"
  [1]=>
  string(154) "Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)"
  ["article_title"]=>
  string(154) "Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)"
  [2]=>
  string(150) "DURHAM, NC, January 16, 2024 – Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic"
  ["short_description"]=>
  string(150) "DURHAM, NC, January 16, 2024 – Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic"
  [3]=>
  string(249) "DURHAM, NC, January 16, 2024 – Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the U.S. Food and Drug Administration..."
  ["description"]=>
  string(249) "DURHAM, NC, January 16, 2024 – Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the U.S. Food and Drug Administration..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(148) "https://www.drugs.com/clinical_trials/atsena-therapeutics-receives-rare-pediatric-designation-fda-atsn-101-gene-therapy-gucy2d-associated-21278.html"
  ["blog_url"]=>
  string(148) "https://www.drugs.com/clinical_trials/atsena-therapeutics-receives-rare-pediatric-designation-fda-atsn-101-gene-therapy-gucy2d-associated-21278.html"
  [15]=>
  string(19) "2024-01-16 12:01:57"
  ["add_date"]=>
  string(19) "2024-01-16 12:01:57"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}